There is a death of literature on the effects of neuroleptics in older schizophrenia patients. In this article, we review the available literature and present findings from our own studies. Neuroleptics are effective in the treatment of late-life schizophrenia, although older patients generally need lower dosages than younger subjects. Neuroleptics, however, carry a relatively high risk of side...

Classical (chlorpromazine, haloperidol) and atypical (sulpiride and clozapine) neuroleptics applied for a period of 2 weeks diminished neuropeptide Y (NPY) levels in nucleus accumbens, but not in striatum. These changes were correlated with NPY mRNA level. However, the effect of these neuroleptics on the level of NPY in hypothalamus was different. It is suggested that changes in NPY levels caus...

BACKGROUND This article reviews the published clinical experience with atypical neuroleptics in children and adolescents. METHOD A computerized literature search was conducted (MEDLINE, 1974-1998) to retrieve all reports on the use of atypical neuroleptics in children and adolescents. A hand search was performed as well. All relevant clinical data were collated by type of drug. RESULTS We f...

BACKGROUND Cytochrome P450 3A (CYP3A) subfamily is involved in the metabolism of xenobiotics (e.g., drugs) and endogenous substances (e.g., steroids). The aim of the present study was to investigate the influence of classic and atypical neuroleptics on the level and activity of CYP3A in rat liver, measured as a rate of testosterone 2β- and 6β-hydroxylation. METHODS The reactions were studied ...

The aim of the present study was to investigate the influence of classic and atypical neuroleptics on the activity of rat CYP2A measured as a rate of testosterone 7alpha-hydroxylation. The reaction was studied in control liver microsomes in the presence of neuroleptics, as well as in microsomes of rats treated intraperitoneally (i.p.) for one day or two weeks (twice a day) with pharmacological ...

BACKGROUND With the introduction of atypical neuroleptic medications into the marketplace, the use of conventional neuroleptics has fallen, attendant with the perception of a more favorable side-effect profile for the atypical neuroleptics. OBJECTIVE The purpose of this study was to determine the risk of tardive dyskinesia (TD) associated with atypical and conventional neuroleptics. METHODS...

Clozapine was approved by the Food and Drug Administration (FDA) in October of 1989 for use through the Clozaril Patient Management System (CPMS). Prior to that date clozapine was prescribed on a "compassionate use" basis at 16 study centers in the U.S. It was used primarily with patients with a diagnosis of schizophrenia and schizoaffective disorder whose symptoms were refractory to traditiona...